A new study led by researchers at Brigham and Women’s Hospital (BWH) has found that a single measurement of plasma glycated CD59 (GCD59), a novel biomarker for diabetes, at weeks 24-28 of gestation identified, with high sensitivity and specificity, women who failed the glucose challenge test as well as women with gestational diabetes. Plasma levels of GCD59 were also associated with the probability of delivering a large-for-gestational-age newborn. These findings were published in Diabetes Care.
The research team’s primary goal was to assess the accuracy of the diabetes biomarker, GCD59, in predicting the results of the standard-of-care glucose challenge test used to screen for gestational diabetes. The team conducted a case-control study of 1,000 pregnant women who were receiving standard prenatal care at BWH: 500 women who had a normal glucose challenge test (control subjects) and 500 women who failed the glucose challenge test and required a subsequent oral glucose tolerance test (case patients). Researchers found that, when compared with the control subjects, the median plasma GCD59 value was 8.5-fold higher in the patients who failed the glucose challenge test and 10-fold higher in the subset of these patients who met diagnostic criteria for gestational diabetes in the subsequent oral glucose tolerance test.
“This is the first study to demonstrate that a single measurement of plasma GCD59 can be used as a simplified method to identify women who are at risk for failing the glucose challenge test and are at higher risk for developing gestational diabetes,” says Jose Halperin, MD, a physician and researcher, Director of the Hematology Laboratory for Translational Research at BWH, and senior author of the publication.
The researchers also found that higher plasma GCD59 levels at gestational week 24-28 were associated with higher prevalence of large-for-gestational-age newborns. Out of the 58 large-for-gestational-age babies born to mothers that failed the glucose challenge test in this study, 80 percent were born to mothers who did not meet oral glucose tolerance test criteria for gestational diabetes, but had median plasma GCD59 levels 7-fold higher than control women with a normal glucose challenge test. These findings are consistent with other studies showing that women who fail the glucose challenge test, but do not meet criteria for gestational diabetes, are still at a higher risk of abnormal pregnancy outcomes, including delivering large-for-gestational-age babies. Currently there are no practice guidelines for the management of women who fall between normal and abnormal glucose tolerance levels and, therefore, their management is the same as that for women with a normal glucose challenge test results.
“These results suggest that a single measurement of plasma GCD59 during weeks 24–28 may also help stratify the risk for delivering larger infants among women with gestational glucose intolerance,” says Dr. Halperin. “Our studies have opened an avenue for larger multicenter studies to further assess the clinical utility of plasma GCD59 for screening and diagnosis of gestational diabetes among the general population of the United States. If our results are confirmed, we’re hopeful that the GCD59 test could be available in clinical practices within the next few years.”
Dr. Halperin and Michael Chorev, MD have a financial interest in Mellitus, LLC, which is developing diagnostic tools for diabetes, including the test described in this research under a license agreement from Harvard University.
This project was supported by the National Institutes of Health grants DK-095424, DK-62294, DK-089206, DK-101442, DK-107407, and HL-111771. It was also funded by the Harvard University Accelerator Fund, now known as the Blavatnik Biomedical Accelerator at Harvard University, and the Doris Duke Charitable Foundation.
Paper cited: Halperin et al. “Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance.” Diabetes Care DOI: 10.2337/dc16-2598.